Viable count and safety assessment of a reduced dose of the Brucella abortus S19 vaccine
Saved in:
| Author: | |
|---|---|
| Status: | Versión publicada |
| Publication Date: | 2026 |
| Description: | The Brucella abortus S19 vaccine remains a key tool in bovine brucellosis control. However, the full recommended dose may induce local reactions and prolonged seropositivity, complicating disease surveillance. To improve vaccine safety and standardization, this study evaluated the safety, viable count consistency, and efficacy of reduced-dose S19 vaccines manufactured in compliance with World Organisation for Animal Health (WOAH) guidelines. The research evaluated the safety and effectiveness of a reduced dose of the live attenuated Brucella abortus strain 19 vaccine, which is commonly used to prevent bovine brucellosis. Vaccine batches were prepared according to WOAH-recommended standards and quantified by viable count methods to ensure accurate colony-forming unit (CFU) concentrations. Formulations delivering the standard CFU dose were tested in guinea pigs and seronegative heifers. Studies have shown that administering the reduced dose subcutaneously is safe even in pregnant cattle, with no significant adverse effects reported. This approach helps reduce the risk of persistent vaccinal infection while still offering protective immunity. The immunogenicity and persistence of the vaccine are directly related to the colony-forming units (CFU) per dose. The reduced dose typically contained around 5 - 8 10 CFU when administered via standard subcutaneous injections. Safety was monitored through observation of local and systemic reactions. All vaccine batches met WOAH quality, purity, and potency requirements. The reduced-dose vaccine demonstrated an appreciable viable count that is still within the recommended range for Brucella abortus S19 vaccine release in accordance with WOAH guidelines, satisfying non-inferiority criteria. Viable count–based standardization of Brucella abortus S19 vaccine doses, in accordance with WOAH manufacturing guidelines, ensures accurate potency control and enhanced batch uniformity. A reduced dose provides equivalent protection with improved safety and reduced serological interference, supporting its potential use in national brucellosis vaccination programs. |
| Country: | Portal de Revistas UNA |
| Institution: | Universidad Nacional de Costa Rica |
| Repositorio: | Portal de Revistas UNA |
| Language: | Inglés |
| OAI Identifier: | oai:www.revistas.una.ac.cr:article/23197 |
| Online Access: | https://www.revistas.una.ac.cr/index.php/veterinaria/article/view/23197 |
| Keyword: | Brucella Brucella abortus Vaccine S19 |